The Hepatitis Market Outlook to 2016
Business Insights
September 26, 2011 7 Pages - SKU: RET6647619
|
|
This report provides comprehensive coverage of the hepatitis market, incorporating a detailed epidemiological analysis. The report analyzes current leading brands, and profiles leading players in the hetpatitis market. It also identifies products in late stage development and forecasts their expected sales performance.
Understand how recent events are affecting the performance of major products, and how their marketers are confronting competitive market changes.
Compare the franchises of the leading companies in the hepatitis market, and understand how the market share of these companies will change.
Evaluate pipeline compounds for the treatment of hepatitis and determine which products will provide the greatest revenue growth.
Understand the market dynamics and interactions between the key drug classes used in the treatment of hepatitis.
Forecast the performance of the leading marketed and pipeline products through to 2016.
The launch of Incivek and Victrelis indicated for the treatment of hepatitis C, is anticipated to change the treatment modality. The drugs are estimated to rapidly reach their peak sales by 2012-13 due to their superior therapeutic profile compared to the currently marketed products.
A strong market opportunity exists in patients less responsive to current hepatitis treatment, including adults over 40 years of age, individuals with chronic renal disease and individuals with HIV. The treatment-failure population, representing approximately 40% of the total hepatitis C infected population, also presents a significant opportunity.
Roche was the global market leader in the treatment of hepatitis with a market share of over 25%. Roche's performance was driven by its hepatitis C products, Copegus and Pegasys. These products represent the current standard of care in this indication where they compete strongly with Pegintron and Rebetol of Merck and Co.
Who were the leading players in the hepatitis market in 2010 and which products were driving their performance?
What are the current market leading products in hepatitis treatment and how will their market position change during the forecast period?
Which of the seven major markets have the greatest market potential for hepatitis therapy?
How will the launch of Victrelis and Incivek impact upon the hepatitis C market?
Please note: this is delivered as a Zip file.
|
- About the author
- Disclaimer
- EXECUTIVE SUMMARY
- Overview and epidemiology of hepatitis
- Global market analysis
- Pipeline analysis
- Competitive landscape
- Overview and epidemiology of hepatitis
- Summary
- Introduction
- Hepatitis A
- Hepatitis B
- Hepatitis C
- Hepatitis D
- Hepatitis E
- Global market analysis
- Summary
- Introduction
- Market analysis by country
- Market analysis by drug class
- Leading brand dynamics
- Pegasys (peginterferon alfa-2a) - Roche
- Hepatitis Vaccines - GSK
- Baraclude (entecavir) - BMS
- PegIntron (peginterferon alfa-2b) - Merck
- Viread (tenofovir disoproxil fumarate) - Gilead Sciences
- Copegus (ribavirin) - Roche
- Rebetol (ribavirin) - Merck
- Hepsera (adefovir dipivoxil) - Gilead
- A new era of treatment for Hepatitis C virus infection
- Protease inhibitors (PIs)
- The competition between Incivek and Victrelis
- Factors governing the market space of Incivek and Victrelis
- Product life cycle and forecast
- Hepatitis market drivers, challenges, and resistors
- Launch of novel drugs for HCV treatment will promote revenue sales growth
- Increased awareness of hepatitis will create a short to medium term sales increase
- Challenges in bridging the treatment gap impedes forecast market uptake
- Warehoused patients seeking new treatment options will temporarily create demand
- Drugs with reduced adverse effects change the treatment modality
- Launch of biosimilars and generics will slow market growth
- The WHO’s approval of the SFDA’s vaccine regulation will increase low cost vaccine supply
- Increasing HIV-HCV/HBV co-infection rates if not reduced will affect sales growth
- Key events
- The FDA grants fast track status to Pharmasset’s PSI-7977 for the treatment of HCV
- Development program for therapeutic intranasal vaccine for treatment of hepatitis B
- Novartis discontinues the development of Joulferon/Zalbin on safety concerns
- GSK signs microRNA deal with Regulus for HCV
- Government initiatives to curb the incidence of hepatitis
- Vertex collaborates with Alios for hepatitis portfolio
- Biosimilars and generics
- Leading hepatitis drugs sales forecast
- Pipeline analysis
- Summary
- Introduction
- Key trends in hepatitis R&D
- Product differentiation will hold the key to success in the hepatitis market
- Multi-billion dollar opportunity for a successful drug class
- The treatment-failure population presents a significant opportunity
- End stage renal disease (ESRD) patients present high potential for vaccines
- Despite the introduction of novel treatments, the SOC for hepatitis C will not change
- Profiles of the key pipeline products
- TMC435 - Medivir/J&J
- BI 201335 - Boehringer Ingelheim
- Vaniprevir (MK-7009) - Merck
- Debio 025 - Novartis/Debiopharm
- Danoprevir (ITMN-191/RG7227) - Roche
- RG-7128 - Roche/ Pharmasset
- ABT-450 - Abbott/Enanta
- BMS-790052 - Bristol-Myers Squibb
- GS-9190 (Tegobuvir) - Gilead Sciences
- GS-9256 - Gilead Sciences
- ACH-1625 - Achillion
- Competitive landscape
- Summary
- Introduction
- Competitive positioning of the leading players in the global hepatitis market
- Roche
- Marketed product portfolio
- Pipeline analysis
- Strategic and growth analysis
- GSK
- Marketed product portfolio
- Pipeline analysis
- Strategic and growth analysis
- Merck & Co.
- Marketed product portfolio
- Pipeline analysis
- Strategic and growth analysis
- Gilead
- Marketed product portfolio
- Pipeline analysis
- Strategic and growth analysis
- Bristol-Myers Squibb
- Marketed product portfolio
- Pipeline analysis
- Strategic and growth analysis
- Appendix
- Scope
- Methodology
- Epidemiology
- Market forecast
- Glossary/Abbreviations
- Abbreviations
- Bibliography/References
Share this report
Other tasks Related Markets Hepatitis Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
